Apurva Prakash

Apurva Prakash

UNVERIFIED PROFILE

Are you Apurva Prakash?   Register this Author

Register author
Apurva Prakash

Apurva Prakash

Publications by authors named "Apurva Prakash"

Are you Apurva Prakash?   Register this Author

25Publications

379Reads

16Profile Views

Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder.

J Child Adolesc Psychopharmacol 2015 May;25(4):293-305

1 Department of Psychiatry, University of Texas Southwestern and Children's Medical Center , Dallas, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/cap.2014.0076DOI Listing
May 2015

A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder.

J Am Acad Child Adolesc Psychiatry 2015 Apr 29;54(4):283-93. Epub 2015 Jan 29.

Johns Hopkins University/Kennedy Krieger Institute, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaac.2015.01.008DOI Listing
April 2015

Pharmacokinetics of orally administered duloxetine in children and adolescents with major depressive disorder.

Clin Pharmacokinet 2014 Aug;53(8):731-40

Lilly Research Laboratories, Eli Lilly and Company, DC 0724, Indianapolis, IN, 46285-0724, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s40262-014-0149
Web Search
http://link.springer.com/10.1007/s40262-014-0149-y
Publisher Site
http://dx.doi.org/10.1007/s40262-014-0149-yDOI Listing
August 2014

Pharmacokinetics of orally administered duloxetine in children and adolescents with major depressive disorder.

Clin Pharmacokinet 2014 Aug;53(8):731-40

Lilly Research Laboratories, Eli Lilly and Company, DC 0724, Indianapolis, IN, 46285-0724, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s40262-014-0149
Web Search
http://link.springer.com/10.1007/s40262-014-0149-y
Publisher Site
http://dx.doi.org/10.1007/s40262-014-0149-yDOI Listing
August 2014

Pharmacokinetics of orally administered duloxetine in children and adolescents with major depressive disorder.

Clin Pharmacokinet 2014 Aug;53(8):731-40

Lilly Research Laboratories, Eli Lilly and Company, DC 0724, Indianapolis, IN, 46285-0724, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s40262-014-0149
Web Search
http://link.springer.com/10.1007/s40262-014-0149-y
Publisher Site
http://dx.doi.org/10.1007/s40262-014-0149-yDOI Listing
August 2014

Evaluation of sentinel node biopsy in locally advanced breast cancer patients who become clinically node-negative after neoadjuvant chemotherapy: a preliminary study.

Int J Breast Cancer 2011 12;2011:870263. Epub 2011 Oct 12.

Departments of Surgery and Pathology, Lady Hardinge Medical College, Shaheed Bhagat Singh Marg, New Delhi 110001, India.

View Article

Download full-text PDF

Source
http://www.hindawi.com/journals/ijbc/2011/870263/
Publisher Site
http://dx.doi.org/10.4061/2011/870263DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262565PMC
August 2012

Addressing methodological issues in studying antidepressant onset efficacy using prespecified sensitivity analyses.

Psychopharmacol Bull 2008 ;41(2):40-54

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.

View Article

Download full-text PDF

Source
March 2012

Early symptom change prediction of remission in depression treatment.

Psychopharmacol Bull 2009 ;42(1):94-107

Department of Psychiatry, University of Texas Health Science Center, San Antonio, TX, USA.

View Article

Download full-text PDF

Source
February 2012

An open-label safety and pharmacokinetics study of duloxetine in pediatric patients with major depression.

J Child Adolesc Psychopharmacol 2012 Feb 17;22(1):48-55. Epub 2012 Jan 17.

Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana 46285, USA.

View Article

Download full-text PDF

Source
http://www.liebertpub.com/doi/10.1089/cap.2011.0072
Publisher Site
http://dx.doi.org/10.1089/cap.2011.0072DOI Listing
February 2012

The clinical importance of changes in the 0 to 10 numeric rating scale for worst, least, and average pain intensity: analyses of data from clinical trials of duloxetine in pain disorders.

J Pain 2010 Feb 8;11(2):109-18. Epub 2009 Aug 8.

Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, PA19041, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpain.2009.06.007DOI Listing
February 2010

Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions.

J Diabetes Complications 2009 Sep-Oct;23(5):349-59. Epub 2008 Sep 2.

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdiacomp.2008.07.004DOI Listing
January 2010

Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram).

Neuropsychobiology 2007 23;56(2-3):73-85. Epub 2007 Nov 23.

Lilly Research Laboratories, Indianapolis, Ind. 46285, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000111537DOI Listing
April 2008

Simple options for improving signal detection in antidepressant clinical trials.

Psychopharmacol Bull 2007 ;40(2):101-14

Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.

View Article

Download full-text PDF

Source
September 2007

Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder.

J Sex Med 2007 Jul;4(4 Pt 1):917-29

Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1743-6109.2007.00520.xDOI Listing
July 2007

Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.

Curr Med Res Opin 2007 Jun 27;23(6):1303-18. Epub 2007 Apr 27.

Department of Psychiatry, University of Florida, Gainesville, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1185/030079907X188107DOI Listing
June 2007

Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.

Depress Anxiety 2007 ;24(1):41-52

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/da.20209DOI Listing
May 2007

Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range.

J Psychiatr Res 2006 Jun 4;40(4):337-48. Epub 2005 Nov 4.

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpsychires.2005.08.010DOI Listing
June 2006

Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder.

Br J Psychiatry 2002 Oct;181:315-20

Novartis Pharmaceuticals, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1192/bjp.181.4.315DOI Listing
October 2002

Fluoxetine versus placebo in posttraumatic stress disorder.

J Clin Psychiatry 2002 Mar;63(3):199-206

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind. 46285, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4088/jcp.v63n0305DOI Listing
March 2002